Search results for " AAV"
Article
Evaluating the Use of Continuous Chromatography
Continuous processes continue to advance in bioprocessing. In downstream processing, continuous chromatography is gaining traction in the purification of protein therapeutics. As the biopharma…
Article
What is process development?
What is process development?
Biopharma process development comprises the activities that help you create a series of steps to produce a biomolecule – a monoclonal antibody (mAb), recomb…
Article
From cells to purified capsids: How to develop a scalable rAAV process
Adeno-associated virus (AAV) is the most common vector for gene therapy, yet there’s much room to improve production, purification, and analytics. In this webinar we present the latest upd…
Article
Recombinant Adeno-Associated Virus Type 5 Production Process
A scalable recombinant adeno-associated virus (rAAV) type 5 production process was developed using transfected HEK293 suspension cells.
READ THE FULL ARTICLE >>
Article
Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.
By Alex Chatel and …
Article
Technology Innovations Improve Process Chromatography Performance
As technology matures, inefficiencies and process limitations in downstream process chromatography are improved.
By Feliza Mirasol
Selecting an appropriate separation technology fo…
Article
Production of Recombinant Adeno-associated Virus Vectors Using Microcarrier Culture of HEK293T Cells
As of March 2020, more than 4310 gene therapy clinical trials have been performed worldwide, with only 518 of them in Phase III and Phase IV. As the gene therapy projects enter clinical Phase III or g…
Article
FDA Seeks to Enhance Manufacturing of Cell and Gene Therapies
FDA Seeks to Enhance Manufacturing of Cell and Gene Therapies
More consistent and reliable production processes are critical for advancing innovative treatments.
By Jill Wechsler
…